Back to discover

Protein / target

C-reactive protein

Encoded byCRPP02741Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
25
Research papers

Protein at a glance

Biological role

Low-density lipoprotein particle receptor binding

Strongest disease association

Pneumonia

Via encoding gene CRP · Genetic evidence · score 0.77

Research activity

Actively researched

25 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine.

View complete UniProt function annotation

Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine. Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells

Subcellular location

Secreted
Domains and Gene Ontology detail (21)

Domains & features

Pentraxin (PTX)

Gene Ontology

  • Cextracellular region
  • Cextracellular space
  • Fcalcium ion binding
  • Fcholine binding
  • Fcomplement component C1q complex binding
  • Fidentical protein binding
  • Flow-density lipoprotein particle binding
  • Flow-density lipoprotein particle receptor binding
  • Pacute-phase response
  • Pdefense response to Gram-positive bacterium
  • Pinflammatory response
  • Pinnate immune response

224 aa · 25 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO
View supporting evidence

Immune signalling

  • ·inflammatory response
  • ·innate immune response
  • ·regulation of interleukin-8 production

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CRP

Gene-level evidence surfaced through the gene CRP that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Pneumonia
0.80Well supported

Genetic evidence dominant · Open Targets 0.50

Bacterial Infections
0.80Well supported

Genetic evidence dominant · Open Targets 0.49

Influenza, Human
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.42

Pneumonia, Bacterial
0.66Moderately supported

Genetic evidence dominant · Open Targets 0.40

Nephritis
0.56Moderately supported

Genetic evidence dominant · Open Targets 0.34

View evidence synthesis (5)
PneumoniaWell supported
0.80
agreement 0.670.94
Genetic84%Literature16%

Open Targets aggregate 0.50 · 2 independent evidence families

Bacterial InfectionsWell supported
0.80
agreement 0.660.94
Genetic84%Literature16%

Open Targets aggregate 0.49 · 2 independent evidence families

Influenza, HumanModerately supported
0.69
agreement 0.550.83
Genetic91%Literature9%

Open Targets aggregate 0.42 · 2 independent evidence families

Pneumonia, BacterialModerately supported
0.66
agreement 0.530.80
Genetic84%Literature16%

Open Targets aggregate 0.40 · 2 independent evidence families

NephritisModerately supported
0.56
agreement 0.420.70
Genetic97%Literature4%

Open Targets aggregate 0.34 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Pneumonia0.50
Bacterial Infections0.49
Influenza, Human0.42
Pneumonia, Bacterial0.40
Nephritis0.34
Prosthesis-Related Infections0.33
Nephritis, Interstitial0.31
Carcinoma, Squamous Cell0.14

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc med conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Structure with LigandSM · High-Quality PocketAB · UniProt loc med confAB · UniProt SigP or TMHMMAB · GO CC med conf

Raw Open Targets tractability assessment buckets, by modality.

Research activity

25 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Circulating miRNAs modulating systemic low-grade inflammation and affecting neurodegeneration.

Van der Auwera S · Progress in neuro-psychopharmacology & biological psychiatry · 2024

Europe PMC papers linked directly to this protein.